Navigation Links
Memory Study Enrolling Participants Evaluating Memory Loss Vitamin
Date:2/1/2010

Quincy Bioscience has announced enrollment is underway for a memory loss study evaluating the impact of Prevagen® on cognitive function. Men and women aged 40 years and older who are experiencing memory loss and can travel to Madison, WI area are encouraged to apply at Madison Memory Study.

(Vocus) February 1, 2010 -- Quincy Bioscience is seeking men and women 40 years and older who are experiencing memory loss to enroll in a study that will evaluate the effects of the brain health supplement Prevagen® on cognitive function. The Prevagen Memory Study is a randomized placebo-controlled, double-blind study that will require five (5) visits for cognitive testing during the three (3) month study period. The impact of Prevagen on brain cell protection will be evaluated using computer-based cognitive testing software. The study is sponsored by Quincy Bioscience, the manufacturer of Prevagen®.

Quincy Bioscience is pleased to collaborate with Cogstate Ltd., a leading cognitive testing software company based in Melbourne, Australia. Cogstate’s proprietary computer-based testing software will be utilized to assess the effect of Prevagen on cognitive performance. “We are excited to utilize the testing software from Cogstate for the Madison Memory Study,” says Quincy Bioscience president Mark Underwood. “Cogstate is an industry leader with extensive research validating the use of its software tools for measuring cognitive effects.”

Prevagen® is the first and only product to use the active ingredient apoaequorin, a calcium-binding protein discovered in jellyfish. In university studies, Prevagen® was proven to protect brain cells.* First launched in in September of 2007, tens of thousands of people have taken Prevagen®.

Interested candidates who are able to travel to Madison, WI may visit Madison Memory Study to apply or call (608) 237-3170 for more information about the study.

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms. Quincy Bioscience is developing health applications of the jellyfish protein apoaequorin for dietary supplement and pharmaceutical products. The company’s first product, Prevagenwas launched in the fall of 2007 and is intended to supplement the loss of critical calcium-binding proteins depleted in the normal course of healthy aging.

 
  • These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

###

Read the full story at http://www.prweb.com/releases/2010/1/prweb3540214.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
2. Scientists synthesize memory in yeast cells
3. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
4. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
5. Scientists synthesize memory in yeast cells
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
8. ASU researchers improve memory devices using nanotech
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
11. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Memory Study Enrolling Participants Evaluating Memory Loss Vitamin
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):